BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 24433955)

  • 1. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epigenetic regulators for cancer therapy.
    Wee S; Dhanak D; Li H; Armstrong SA; Copeland RA; Sims R; Baylin SB; Liu XS; Schweizer L
    Ann N Y Acad Sci; 2014 Feb; 1309():30-6. PubMed ID: 24571255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 5. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer.
    Yamamura A; Miura K; Karasawa H; Morishita K; Abe K; Mizuguchi Y; Saiki Y; Fukushige S; Kaneko N; Sase T; Nagase H; Sunamura M; Motoi F; Egawa S; Shibata C; Unno M; Sasaki I; Horii A
    Biochem Biophys Res Commun; 2013 Nov; 441(1):102-7. PubMed ID: 24134849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics and ovarian cancer.
    Nephew KP; Balch C; Zhang S; Huang TH
    Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
    [No Abstract]   [Full Text] [Related]  

  • 13. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
    Katz TA; Huang Y; Davidson NE; Jankowitz RC
    Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.
    Lin J; Wang C; Kelly WK
    Semin Oncol; 2013 Jun; 40(3):393-401. PubMed ID: 23806502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.